Metformin for prevention and treatment of colon cancer: A reappraisal of experimental and clinical data

Current Drug Targets

Volumn 17, Issue 4, 2016, Pages 439-446

  Anisimov, Vladimir N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Colorectal cancer; Metformin; Prevention; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AZOXYMETHANE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTIDIABETIC AGENT;

ABERRANT CRYPT FOCUS; ANTINEOPLASTIC ACTIVITY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; ENZYME ACTIVITY; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; COLONIC NEOPLASMS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG REPOSITIONING; DRUG SCREENING; MOUSE;

ANIMALS; CELL PROLIFERATION; COLONIC NEOPLASMS; DIABETES MELLITUS, TYPE 2; DRUG REPOSITIONING; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84960099842     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150309113305     Document Type: Review

References (91)

1. Globocan 2013, Cancer Fact Sheets for Colorectal Cancer. Available from: URL:http://globocan.iarc.fr/Pages/fact_sheetscancer.aspx
2. Neilan BA. Colorectal cancer. In: Balducci L, Lyman GH, Ershler WB, Extermann M, Eds. Comprehensive geriatric oncology, 2nd ed, London & New York: Taylor & Francis Group 2004; pp 710-7.
3. Stegel R, Naishadham D, Jemal A. Cancer statistics 2012. Cancer J Climn 2012; 62:10-29.
4. Dilman VM. Development, aging and disease. a new rationale for an intervention. Chur: Harwood Academic Publishers 1994.
5. Colangelo LA, Gapstur SM, Gann PH, et al. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11: 385-91.
6. Hernández-Díaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010; 53: 802-8.
7. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001; 86: 3574-78.
8. Pozharisski KM, Likhachev AJ, Klimashevski VF, Shaposhnikov JD. Experimental intestinal cancer with special reference to human pathology. Adv Cancer Res 1979; 30: 165-237.
9. Maskens AP. Multistep carcinogenesis in the colon mucosa. In: Maskens AP, Ebbsen P, Burny A, Eds. Concepts and Theories in Carcinogenesis. Amsterdam: Excerpta Medica 1987; pp221-42.
10. Laplante M, Sabartini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
11. Blagosklonny MV. Validation of anti-aging drugs by treating agerelated diseases. Aging 2009; 1: 281-8.
12. Blagosklonny MV. Selective anti-cancer agents as anti-aging drugs. Cancer Biol Ther 2013; 14: 1092-7.
13. Parhitko AA, Favorova OO, Khabibullin DI, Anisimov VN, Henske EP. Kinase mTOR; Regulation and role in maintenance of cellular homeostasis, tumor devleopement and aging. Biochemistry (Moscow) 2014; 79: 88-101.
14. Wang X-W, Zhang Y-J. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol 2014; 20: 4178-88.
15. Taubes G. Cancer prevention with a diabetes pill? Science 2012; 335: 29.
16. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53- deficient tumor cell growth. Cancer Res 2007; 67: 6745-52.
17. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer. Doses, mechanisms and the dandelion and hermetic phenomena. Cell Cycle 2010; 9: 1057-64.
18. Javeshghani S, Zakikhani M, Austin S, et al. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res 2012; 72: 6257-67.
19. Violet B, Guigass B, Sanz Garcia N, et al. Cellar and molecular mechanisms of metformin: an overview. Clin Sci 2012; 122: 253-70.
20. Aldea M, Craciun L, Tomuleasa C, Berindan-Neagoe I, et al. Repositioning metformin in cancer: genetic, drug targets, and new ways of delivery. Tumor Biol 2014; 35(6): 5101-10.
21. Menendez JA, Joven J. Energy metabolism and metabolic sensors in stem cells: The metabostem crossroads of aging and cancer. Adv Exp Med Biol 2014; 824: 117-39.
22. Zhang Y, Guan M, Zhebg Z, Zhang Q, Gao F, Xue Y. Effects of metformin on CS133+ colorectal cancer cells in diabetic patients. PLoS ONE 2013; 8(11): e81264.
23. Adrzejewski S, Grave S-P, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer & Metabolism 2014; 2: 12. http://www.cancerandmetabolism.com/content/2/1/12.
24. Quinn BJ, Dallos M, Kitagawa H, et al. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) 2013; 6: 801-10.
25. Anisimov VN, Pozharisski KM, Dilman VM. Effect of phenformin on the blastomogenic action of 1,2-dimethylhydrazine in rats. Vopr Onkol 1980; 26(8): 54-8.
26. Dilman VM, Sofronov BN, Anisimov VN, Nazarov PG, Lvovich EG. Phenformin elimination of the immunodepression caused by 1,2-dimethylhydrazine in rats. Vopr Onkol 1977; 23(8): 50-4.
27. Shimomoto T, Luo Y, Ohmori H, et al. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethan-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. J Gastroenterol 2012; 47: 1073-83.
28. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTENdeficient mice. Biochem J 2008; 412: 211-21.
29. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008; 99: 2136-41.
30. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010; 49: 662-71.
31. Abd AH, Hussein AG, Mahmood AS. Efficacy of intraperitoneal administration of metformin and 5-fluoruracil in prevention of induced colorectal aberrant crypt foci in mice. Int J Parmacy Phrmaceut Sci 2014; 6: 305-8.
32. Li W, Wang QL, Liu X, et al. Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res (Phila) 2014; 8(2): 139-48.
33. Rao CV, Janakiram NB, Mohammed A, et al. Lack of chemopreventive effects of metformin in azoxymethane-induced rat colon carcinogenesis. Cancer Prev Res 2011; 4(Suppl 10): B42.
34. Madka V, Zhang Y, Brewer M, et al. Chemoprventive efficacy of bisphosphonates, Zometa and Fosamax, alone or in combination with phenformin in AO-induced rat colon cancer model. Cancer Prev Res 2013; 6 (11 Suppl).
35. Zaafar DK, Zaitone SA, Moustafa YM. Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation. PLoS One 2014; 9(6):e100562.
36. Ito K, Ishigamori R, Mutoh M, et al. Ay allele promotes azoxymethane-induced colorectal carcinogenesis by macrophage migration in hyperlipidemic/diabetic KK mice. Cancer Sci 2013; 104(7): 835-43.
37. Markowitz SD, Bertagnoli MM. Molecular origins of cancer: molecular basis for colorectal cancer. N Engl J Med 2009; 361: 2449-60.
38. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20: 4270-434.
39. Mountjoy KG, Finlay GJ, Holdaway IM. Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro. J Endocrinol Invest 1987; 10: 553-7.
40. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008; 1: 369-75.
41. Moon HS, Mantzoros CS. Adiponectin and metformin additively attenuate IL1β-induced malignant potential of colon cancer. Endocr Relat Cancer 2013; 20: 849-59.
42. Nangia-Makker P, Yu Y, Vasudevan A, et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One 2014; 9(1): e84369.
43. Habibollahi P, van den Berg NS, Kuruppu D, et al. Metformin - an adjunct antineoplastic therapy-divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med 2013; 54: 252-8.
44. Feng YH, Wu CL, Shiau AL, et al. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med 2012; 29: 920-6.
45. Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism 2014; 63: 188-93.
46. Lea MA, Chacko J, Bolikal S, et al. Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res 2011; 31: 421-6.
47. Zhou XZ, Xue YM, Zhu B, Sha JP. Effects of metformin on proliferation of human colon carcinoma cell line SW-480. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 1935-8, 1942.
48. Lea MA, Qureshi MS, Buxhoeveden M, et al. Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, in- cluding 3-bromopyruvate, 2-deoxyglucose and biguanides. Anticancer Res 2013; 33: 401-7.
49. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012; 29: 1314-27.
50. Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol 2013; 705: 96-108.
51. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem Pharmacol 2013; 86: 339-350.
52. Lea MA, Pourat J, Patel R, desBordes C. Growth inhibition of colon cancer cells by compounds affecting AMPK activity. World J Gastrointest Oncol 2014; 6(7): 244-52.
53. Algire C, Amrein L, Zakikhani M, et al. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010; 17: 351-60.
54. Dilman VM, Berstein LM, Ostroumova MN, et al. Metabolic immunodepression and metabolic immunotherapy, an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 1982; 39: 13-19.
55. Dilman VM, Berstein LM, Yevtushenko TP, et al. Preliminary evidence on metabolic rehabilitation in cancer patients. Arch Geschwulstforsch 1988; 58: 175-183.
56. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol 2010; 6: 1313-1323.
57. Berstein LM. Biguanides: An expansion to practical oncology (past and present). St.Petersburg: Aesculap, 2010.
58. Currie CJ, Poole CD, Gale EA. The influence of glucoseloweringtherapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
59. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a metaanalysis. Diabetes Care 2011; 34: 2323-8.
60. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013 29; 203-218
61. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010; 3: 1077-83.
62. Higurashi T, Takahashi H, Endo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012; 12: 118.
63. Cardel M, Jensen SM, Pottegard A, Jorgensen TL, Hallas J. Longterm use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med 2014; 3(5): 1458-66.
64. Mei ZB, Zhang ZJ, Liu CY, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One 2014; 9(3): e91818.
65. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist 2013; 18: 1248-58.
66. Kasznicki J, Sliwinska A, Drzewoski ZJ. Metformin in cancer prevention and therapy. Ann Transl Med 2014; 2(6): 57.
67. Anisimov VN, Ukraintseva SV, Yashin AI. Cancer in rodents: does it tell us about cancer in humans? Nature Rev Cancer 2005; 5: 807-19.
68. Chandel N. Four key questions about metformin and cancer. BMC Biology 2014; 12: 85.
69. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetica of metfromin. Clin Pharmacokinet 2011; 50: 81-98.
70. Pollak M. Potential applications fpr biguanides in oncology. J Clin Invest 103; 123: 369370.
71. Wilcock C, Baiey C. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 49-57.
72. Quinn BJ, Kitagawa H, Memmott RM, Gill JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trens Endocr Metab 2013; 24: 469-480.
73. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685-93.
74. Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9: 188-97.
75. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7: 2769-73.
76. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2: 760-74.
77. Smiechowski B, Azoulay L, Yin H, Pollak M, Sussa S. The use of metformin and colotrectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2013; 22: 1877-83.
78. Anisimov V. Do metformin a real anti-carcinogen? A critical reappraisal of experimental data. Ann Trans Med 2014; 2(6): 60.
79. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510: 542-6.
80. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-45.
81. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?" Aging (Albany NY) 2012; 4: 861-7.
82. Anisimov VN, Bartke A. The key role of growth hormone-insulin- IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87(3): 201-23.
83. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-43.
84. +/- mice. Aging (Albany NY) 2012; 4: 709-17.
85. -/- mice by delaying. Aging (Albany NY) 2012; 4: 715-22.
86. +/- mice by inhibiting neuroendocrine tumors. Aging (Albany NY) 2013; 5: 100-10.
87. Anisimov VN. Carcinogenesis and aging. vols 1 & 2. Boca Raton, FL: CRC Press 1987.
88. Anisimov VN. Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev 2009; 130: 105-21.
89. Zhang G, Li J, Purkayastha S, et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature 2013; 497: 211-6.
90. Moiseeva O, Deschênes-Simard X, St-Germain E, et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 2013; 12: 489-9.
91. Anisimov VN. Metformin and rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer. Aging (Albany NY) 2013; 5: 337-8.